Limits...
Strategy for Designing a Synthetic Tumor Vaccine: Multi-Component, Multivalency and Antigen Modification.

Huang ZH, Sun ZY, Gao Y, Chen PG, Liu YF, Chen YX, Li YM - Vaccines (Basel) (2014)

Bottom Line: However, the limitation of the specificity and efficiency of the synthetic tumor vaccines need further improvements.To overcome these difficulties, additional tumor-associated targets need to be identified, and optimized structural designs of vaccines need to be elaborated.In this review, we summarized the main strategies pursued in the design of synthetic tumor vaccines, such as multi-component, multivalency, antigen modification and other possible ways to improve the efficiency of synthetic tumor vaccines.

View Article: PubMed Central - PubMed

Affiliation: Department of Chemistry, Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education), Tsinghua University, Beijing 100084, China. huangzh05@mails.tsinghua.edu.cn.

ABSTRACT
Synthetic tumor vaccines have been proven to be promising for cancer immunotherapy. However, the limitation of the specificity and efficiency of the synthetic tumor vaccines need further improvements. To overcome these difficulties, additional tumor-associated targets need to be identified, and optimized structural designs of vaccines need to be elaborated. In this review, we summarized the main strategies pursued in the design of synthetic tumor vaccines, such as multi-component, multivalency, antigen modification and other possible ways to improve the efficiency of synthetic tumor vaccines.

No MeSH data available.


Multivalent template of calixarene.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4494217&req=5

vaccines-02-00549-f008: Multivalent template of calixarene.

Mentions: Spadoro and co-workers designed four-valent and eight-valent vaccines using calixarene to present the PDTRP motif from MUC1. The TLR2 agonist was introduced to the template by the ether group, and the vaccine produced antibodies against the PDTRP motif (Figure 8) [59].


Strategy for Designing a Synthetic Tumor Vaccine: Multi-Component, Multivalency and Antigen Modification.

Huang ZH, Sun ZY, Gao Y, Chen PG, Liu YF, Chen YX, Li YM - Vaccines (Basel) (2014)

Multivalent template of calixarene.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4494217&req=5

vaccines-02-00549-f008: Multivalent template of calixarene.
Mentions: Spadoro and co-workers designed four-valent and eight-valent vaccines using calixarene to present the PDTRP motif from MUC1. The TLR2 agonist was introduced to the template by the ether group, and the vaccine produced antibodies against the PDTRP motif (Figure 8) [59].

Bottom Line: However, the limitation of the specificity and efficiency of the synthetic tumor vaccines need further improvements.To overcome these difficulties, additional tumor-associated targets need to be identified, and optimized structural designs of vaccines need to be elaborated.In this review, we summarized the main strategies pursued in the design of synthetic tumor vaccines, such as multi-component, multivalency, antigen modification and other possible ways to improve the efficiency of synthetic tumor vaccines.

View Article: PubMed Central - PubMed

Affiliation: Department of Chemistry, Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education), Tsinghua University, Beijing 100084, China. huangzh05@mails.tsinghua.edu.cn.

ABSTRACT
Synthetic tumor vaccines have been proven to be promising for cancer immunotherapy. However, the limitation of the specificity and efficiency of the synthetic tumor vaccines need further improvements. To overcome these difficulties, additional tumor-associated targets need to be identified, and optimized structural designs of vaccines need to be elaborated. In this review, we summarized the main strategies pursued in the design of synthetic tumor vaccines, such as multi-component, multivalency, antigen modification and other possible ways to improve the efficiency of synthetic tumor vaccines.

No MeSH data available.